WO1996015111A9 - Method and intermediates for the synthesis of korupensamines - Google Patents

Method and intermediates for the synthesis of korupensamines

Info

Publication number
WO1996015111A9
WO1996015111A9 PCT/US1995/014896 US9514896W WO9615111A9 WO 1996015111 A9 WO1996015111 A9 WO 1996015111A9 US 9514896 W US9514896 W US 9514896W WO 9615111 A9 WO9615111 A9 WO 9615111A9
Authority
WO
WIPO (PCT)
Prior art keywords
compound
benzyl
acid
alkyl
protecting group
Prior art date
Application number
PCT/US1995/014896
Other languages
French (fr)
Other versions
WO1996015111A1 (en
Filing date
Publication date
Priority claimed from US08/339,958 external-priority patent/US5543523A/en
Application filed filed Critical
Priority to AU42378/96A priority Critical patent/AU4237896A/en
Publication of WO1996015111A1 publication Critical patent/WO1996015111A1/en
Publication of WO1996015111A9 publication Critical patent/WO1996015111A9/en

Links

Definitions

  • Michellamines A (1), B (2), and C (3) constitute a family of anti-
  • Michellamine B possesses a multilevel mode of action including an inhibition of the viral reverse transcriptase as well as blockage of cellular fusion and synctium formation.
  • michellamine B has been selected by the National Cancer Institute for INDA-directed preciinical development. See, for example, K.P. Manfredi et al., J. Med. Chem.. 34, 3402 (1991) and M.R. Boyd et al., J. Med. Chem.. 37. 1740 (1994).
  • Atropisomers 1-3 are unique among known naphthylisoquinoline alkaloids in their dimeric nature, in the locus of the naphthalene to isoquinoline biaryl bond, and in the extent of free hydroxyl group adornment.
  • the relative configurations of the stereogenic biaryl axes in each of 1-3 were established by identification of NOE interactions between the peri-H( 1 ') and -H(l'") and one or the other of the diastereotopic protons at C(4) and C(4'").
  • the absolute configurations at C(1)/C(T") and C(3)/C(3'") were assigned by degradation to ⁇ -alanine and ⁇ -3-aminobutyric acid, respectively. See, M.R. Boyd et al., as cited above, G. Bringmann et al., Angew. Chem. Int. Ed. Eng.. 32, 1190 (1993) and G. Bringmann et al., Tetrahedron. 32, 9643 (1994).
  • the configurations at 5/8' and 875"' of michellamines A. B and C are S/S, S/R and R/R, respectively.
  • swsTmjresBEr r ⁇ iiB Compound 4 1 has been referred to as korupensamine B by G. Bringmann et al., J. Org. Chem..52, 6349 (1994). In view of the ability to synthesize michellamines from these compounds in no more than five steps, a need exists for synthetic methods and intermediates which can be employed to prepare korupensamines.
  • the present invention provides intermediates useful for the synthesis of korupensamines and thus for the synthesis of michellamines and their analogs.
  • the present invention provides a compound of the general formula (I):
  • X is Br, Cl or I
  • Y is H, (C,-C 4 )alkyl, benzyl, or CHO
  • each of R 1 and R 2 is H or CH 3 and each of R 3 and R 4 is H, (C ⁇ -C 4 )alkyl, benzyl, (C 2 -Cs)acyl, or an acid-labile hydroxy protecting group such as (C ⁇ -C 4 )alkoxy(C,-C 4 )alkyl, tetrahydropyranyl, or (R 8 ) 3 Si, wherein each R 8 is (Cj-C 4 )alkyl.
  • X is I
  • R 1 and R 2 are CH 3
  • a broken line indicates a bond that extends below the plane of the ring, i.e., below the plane of the page, and a wedged line indicates a bond that extends above the plane of the page.
  • the U?,3/?-isomer of (I) is employed.
  • the present invention also provides compounds of the formula (II):
  • R 6 is Cl, Br, I, B(OH)2, an anhydride or ester of B(OH) 2 , or OSO2R 9 , wherein R 9 is (C ⁇ -C 4 )perfluoroalkyl, and each of R 5 and R 7 is H, (C ⁇ -C4)alkyl, benzyl, (C 2 -Cs)acyl or an acid-labile hydroxy protecting group, as described above.
  • R 6 is Br or B(OH)2
  • R 5 is an acid-labile protecting group
  • R 7 is H or CH 3 .
  • the compound of formula II wherein R 6 is B(OH)2 can be prepared from a compound of formula II wherein R 6 is halo, by lithiation and reaction of the lithiated compound with B(OMe)3, following protection of the two OH groups, i.e., wherein R 5 and R 7 are not H or acyl.
  • a further aspect of the present invention is a method to prepare a korupensamine, preferably korupensamine A or B, or an analog thereof comprising:
  • R 5 is benzyl, (C2-Cs)acyl or an acid-labile hydroxy protecting group, R 6 is B(OH)2, and R 7 is (C ⁇ -C4)alkyl; in the presence of a Pd(0) catalyst and an inorganic base in an organic solvent, to yield a compound of the formula (V):
  • R 1 and R 2 are each H or CH3, R 7 is (Cj - C 4 )alkyl, and Y, R 2 , R 3 , R 4 , and R 5 are H.
  • R 1 , R 2 and R 7 are CH3, R 5 is an acid-labile protecting group, preferably methoxymethyl, that is subsequently removed by exposing V to dilute aqueous acid, and Y, R 3 and R 4 are benzyl that are subsequently removed by hydrogenolysis.
  • the l/?,3R-isomer of III is employed, which yields a mixture of korupensamines A and C.
  • Figure 1 is a reaction scheme summarizing the reaction of compounds 8 and 13 to yield korupensamine derivatives S-14 and R-14, and the conversion of these compounds to michellamines A-C.
  • SBBS ⁇ iTE SHEET (Rffll 28 Generally, demethylation of 7 yields a compound of formula I wherein Y, R 3 and R 4 are H, and the hydroxyl groups can be reacted with other protecting groups, such as those disclosed hereinabove.
  • the iodo moiety can be replaced by Br or Cl by a variety of halogen exchange reactions, such as by lithiation, following reaction with elemental halogen.
  • Replacement of (R)-PhCH (Me)NH 2 with PhCH 2 NH 2 and/or reaction with the corresponding 3,5-dimethoxyphenylacetaldehyde yields compounds of formula I wherein R 1 and/or R 2 is H.
  • MOM methoxymethyl
  • the palladium(O) catalyzed cross-coupling of 8 with 13 provided an about 4:3 ratio of the hindered atropisomers S-14 and R-14 (40-80%).
  • Palladium(O) catalyzed cross-coupling is typically carried out in the presence of a base and an organic solvent.
  • a preferred embodiment of the invention utilizes tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3) 4 ) as the source of palladium(O) catalyst, saturated sodium bicarbonate (NaHCO 3 ) as the base and toluene as the organic solvent.
  • Pd(0) catalysts include those disclosed in Larock et al. (U.S. Patent No.
  • Bases useful in the present invention are those which are adequately soluble in the reaction medium. Although an inorganic base is preferred, an organic base can also be used. Representative bases are disclosed at Col. 7 of the Larock et al. patent, and Col. 7 of the Blaser et al. patent, as cited above.
  • Suitable organic solvents include, in addition to the preferred toluene, tetrahydrofuran, ethers, glycol ethers, dimethylsulfoxide, dimethyl forma ide, acetonitrile, acetamide, dimethylacetamide, and hexamethylphosphoramide.
  • Michellamines A-C were cleanly (as judged from the crude l H NMR spectrum) produced with nearly quantitative mass recovery. Separation of a small portion on amino-bonded phase [7:1 CH 2 Cl2:0.1 weight % (NH4) 2 CC> 3 in methanol] has thus far provided a pure sample of michellamine A (1) along with an about 2: 1 mixture of michellamines B (2) and C (3), as determined by NMR analysis.
  • the invention will further be described by reference to the following detailed examples.
  • reaction mixture was immediately allowed to warm to room temperature and stir. After 10 h, the flask was cooled to -78 °C and carefully quenched with 1.5 mL of MeOH. The stir bar was removed and the reaction mixture was concentrated in vacuo to yield a brown oil.
  • N-benzyl-(lR, 3R)- 1,2,3,4- tetrahydro-6,8-dimethoxy-l,3-dimethylisoquinoline 62 mg, 0.2 mmol
  • acetic acid 1 mL
  • sodium iodide 120 mg, 0.8 mmol
  • concentrated aqueous hydrobromic acid 49%, 2 mL
  • a solution of dimethyl sulfate (2.52 g, 20.0 mmol) in methylene chloride (20 mL) was prepared in a 100 mL round bottom flask. To the flask was added a solution of tetrabutyl-ammonium bromide (2.25 g, 7.0 mmol) and sodium hydroxide (400 mg, 10.0 mmol) in water (15 mL). To this mixture was added a solution of compound 113 (1.335 g, 5 mmol) in methylene chloride (10 mL). The reaction mixture was stirred at room temperature for 18 h and then diluted with methylene chloride (20 mL).
  • bromide 111 (1.10 g, 3.54 mmol) freshly distilled THF (10 mL). Under nitrogen, the solution was cooled to - 78 °C and then n-butyllithium (2.5 M in hexane, 1.7 mL, 4.2 mmol) was added. The resulting solution was stirred for 15 minutes, after which time a precipitate appeared. Trimethyl borate (1.7 mL, 14.4 mmol) was added to the flask and a clear solution formed. The mixture was stirred at - 78 °C for 30 min and then at room temperature for 2 h.
  • Compound 14 was obtained from boronic acid 13 and iodide 8 in 81% yield with a 4:3 ratio of S-14 to R-14.
  • the product was purified by MPLC (hexanes/EtOAc/Et 3 N; 3:1:0.1); ifi.
  • N-benzyl-(lR, 3R)-5-iodo- l,2,3,4-tetrahydro-6,8-dimethoxy-l,3-dimethylisoquinoline [107] (66 mg, 0.15 mmol) and toluene (3 mL).
  • compound 120 (58 mg, 0.23 mmol), which resulted in the formation of a slurry.
  • a minimum amount of ethanol was added to change the slurry to a clear solution.
  • reaction mixture was stirred until TLC analysis indicated no starting material and possible intermediate left.
  • the catalyst was removed by passing through a bed of Celite. The filtrate was concentrated in vacuo to yield deprotected monomer.

Abstract

A method of preparing a korupensamine or an analog thereof comprising: (a) reacting a compound of formula (III), wherein each of R?1 and R2¿ is CH¿3? or H, X is I, Y is (C1-C4)alkyl, benzyl or CHO, and each of R?3 and R4¿ is (C¿1?-C4)alkyl, benzyl, (C2-C5)acyl or an acid-labile hydroxy protecting group; with a compound of formula (IV), wherein R?5¿ is benzyl, (C¿2?-C5)acyl or an acid-labile hydroxy protecting group, R?6¿ is B(OH)¿2?, and R?7¿ is (C¿1?-C4)alkyl; in the presence of a Pd(0) catalyst and an inorganic base in an organic solvent, to yield a compound of formula (V), wherein Y, R?1, R2, R3, R4, R5 and R7¿ are as defined above for compounds of formula (III) and (IV). Additionally the intermediates of formula (III), wherein X is Br, Cl or I, Y is H, (C¿1?-C4)alkyl, benzyl, or CHO, each of R?1 and R2 is H or CH3, R?3¿ is a protecting group selected from the group consisting of (C¿1?-C4)alkyl, benzyl, (C2-C5)acyl and an acid-labile hydroxy protecting group; and R?4¿ is H or (C¿2?-C5)acyl; or wherein X is Br, Cl or I, Y is H, (C1-C4)alkyl, benzyl, or CHO, each of R?1 and R2¿ is H or CH¿5, R?3 is H or (C¿2?-C5)acyl and R?4¿ is a protecting group selected from the group consisting of (C¿1?-C4)alkyl, benzyl, (C2-C5)acyl and an acid-labile hydroxy protecting group; and the intermediates of formula (IV), wherein R?6¿ is Cl, Br, I, B(OH)¿2?, an anhydride or ester of B(OH)2, or OSO2R?9¿, wherein R9 is (C¿1?-C4)perfluoroalkyl, and each of R?5 and R7¿ is H, (C¿1?-C4)alkyl, benzyl, (C2-C5)acyl or an acid-labile hydroxy protecting group.

Description

METHOD AND INTERMEDIATES FOR THE SYNTHESIS OF KORUPENSAMINES
Background of the Invention
Michellamines A (1), B (2), and C (3) constitute a family of anti-
HIV, atropisomeric, naphthylisoquinoline alkaloids. All are fully protective against both HIV-1 and HTV-2 infected CEM-SS cells with EC50 values of 2-13 μM. Michellamine B, the most studied and most prevalent of the group, completely protects MT-2 cells from both AZT-resistant and pyridone-resistant strains of HTV- 1. The structure of michellamine B is shown below:
Figure imgf000003_0001
Michellamine B (2)
Michellamine B possesses a multilevel mode of action including an inhibition of the viral reverse transcriptase as well as blockage of cellular fusion and synctium formation. In light of these promising properties, as well as favorable initial toxicity evaluation, michellamine B has been selected by the National Cancer Institute for INDA-directed preciinical development. See, for example, K.P. Manfredi et al., J. Med. Chem.. 34, 3402 (1991) and M.R. Boyd et al., J. Med. Chem.. 37. 1740 (1994).
The michellamines were isolated from a previously unidentified plant, Ancistrocladus korupensis—a. liana found only in the rain forest of a limited region in Cameroon. Supply continuity and sufficiency are important concerns for further drug development. Atropisomers 1-3 are unique among known naphthylisoquinoline alkaloids in their dimeric nature, in the locus of the naphthalene to isoquinoline biaryl bond, and in the extent of free hydroxyl group adornment. The relative configurations of the stereogenic biaryl axes in each of 1-3 were established by identification of NOE interactions between the peri-H( 1 ') and -H(l'") and one or the other of the diastereotopic protons at C(4) and C(4'"). The absolute configurations at C(1)/C(T") and C(3)/C(3'") were assigned by degradation to Λ-alanine and Λ-3-aminobutyric acid, respectively. See, M.R. Boyd et al., as cited above, G. Bringmann et al., Angew. Chem. Int. Ed. Eng.. 32, 1190 (1993) and G. Bringmann et al., Tetrahedron. 32, 9643 (1994). The configurations at 5/8' and 875"' of michellamines A. B and C are S/S, S/R and R/R, respectively.
Two syntheses of michellamine A were recently described by G. Bringmann et al., Tetrahedron. 32, 9643 (1994), and T.R. Kelly et al., Tetrahedron Lett.. 35, 7621 (1994). An acyl derivative of a sample of the natural product korupensamine A (4), which co-exists with the michellamines in the plant, was oxidatively dimerized with silver oxide to yield a binaphthylidendione, which was reduced and deacylated to yield michellamine A. The structure of korupensamine A (4) and its atropisomer ("korupensamine C" (4')) are shown below:
Figure imgf000004_0001
Korupensamine A (4) Korupensamine C (4')
swsTmjresBEr røiiB Compound 41 has been referred to as korupensamine B by G. Bringmann et al., J. Org. Chem..52, 6349 (1994). In view of the ability to synthesize michellamines from these compounds in no more than five steps, a need exists for synthetic methods and intermediates which can be employed to prepare korupensamines.
Summary of the Invention The present invention provides intermediates useful for the synthesis of korupensamines and thus for the synthesis of michellamines and their analogs. For example, the present invention provides a compound of the general formula (I):
Figure imgf000005_0001
wherein X is Br, Cl or I; Y is H, (C,-C4)alkyl, benzyl, or CHO; each of R1 and R2 is H or CH3 and each of R3 and R4 is H, (Cι-C4)alkyl, benzyl, (C2-Cs)acyl, or an acid-labile hydroxy protecting group such as (Cι-C4)alkoxy(C,-C4)alkyl, tetrahydropyranyl, or (R8)3Si, wherein each R8 is (Cj-C4)alkyl. Preferably, X is I, R1 and R2 are CH3, and R3, R4 and Y are the same protecting group, i.e., R3=R4 =γ=benzyl.
As shown in compound 2, a broken line indicates a bond that extends below the plane of the ring, i.e., below the plane of the page, and a wedged line indicates a bond that extends above the plane of the page. Thus, to prepare korupensamines A and C, the U?,3/?-isomer of (I) is employed. However, the procedures disclosed by G. Bringmann et al., cited above, permit the preparation of all the 1,3-isomers of formula (I), wherein X=H; hence all the 1,3-isomers of formula (I) are considered to be within the scope of the invention.
The present invention also provides compounds of the formula (II):
S8BSTIT0TE SHEET RBIE 28
Figure imgf000006_0001
wherein R6 is Cl, Br, I, B(OH)2, an anhydride or ester of B(OH)2, or OSO2R9, wherein R9 is (Cι-C4)perfluoroalkyl, and each of R5 and R7 is H, (Cι-C4)alkyl, benzyl, (C2-Cs)acyl or an acid-labile hydroxy protecting group, as described above. Preferably, R6 is Br or B(OH)2, R5 is an acid-labile protecting group, and R7 is H or CH3.
The compound of formula II wherein R6 is B(OH)2 can be prepared from a compound of formula II wherein R6 is halo, by lithiation and reaction of the lithiated compound with B(OMe)3, following protection of the two OH groups, i.e., wherein R5 and R7 are not H or acyl. The compound of formula II wherein R6 is B(OH)2 and R5 and R7 are not H or acyl can be coupled via Pd(0) catalyzed coupling with a compound of formula I, wherein X is I, Ri=R2=CH3, and R3, R4 and Y are not H, to yield N- and 6,8,4',5' hydroxyl- protected korupensamines. Selective removal of the 5' hydroxyl protecting group, followed by oxidative 676' coupling, reduction and, if necessary, removal of the remaining R3, R4 and Y protecting groups, wherein R7 is CH3, affords a mixture of michellamines A-C, which can be separated by chromatographic techniques. Thus, a further aspect of the present invention is a method to prepare a korupensamine, preferably korupensamine A or B, or an analog thereof comprising:
(a) reacting a compound of the formula (ID):
Figure imgf000006_0002
SβSππiTE SHEET (R8LE 21) wherein each of R1 and R2 is CH3 or H, X is I, Y is (Cι-C4)alkyl, benzyl or CHO, and each of R3 and R4 is (Cι-C4)alkyl, benzyl, (C2-Cs)acyl or an acid- labile hydroxy protecting group; with a compound of the formula (IV):
Figure imgf000007_0001
wherein R5 is benzyl, (C2-Cs)acyl or an acid-labile hydroxy protecting group, R6 is B(OH)2, and R7 is (Cι-C4)alkyl; in the presence of a Pd(0) catalyst and an inorganic base in an organic solvent, to yield a compound of the formula (V):
Figure imgf000007_0002
wherein Y, R1, R2, R3, R4, R5 and R7 are as defined above; and
(b) removing protecting groups R3, R4, R5 and Y to yield a compound of formula V wherein R1 and R2 are each H or CH3, R7 is (Cj - C4)alkyl, and Y, R2, R3, R4, and R5 are H. Preferably, R1 , R2 and R7 are CH3, R5 is an acid-labile protecting group, preferably methoxymethyl, that is subsequently removed by exposing V to dilute aqueous acid, and Y, R3 and R4 are benzyl that are subsequently removed by hydrogenolysis. Most preferably, the l/?,3R-isomer of III is employed, which yields a mixture of korupensamines A and C.
SϊβSTιTUlΕSlEr R8-f2$ Brief Description of the Figures Figure 1 is a reaction scheme summarizing the reaction of compounds 8 and 13 to yield korupensamine derivatives S-14 and R-14, and the conversion of these compounds to michellamines A-C.
Detailed Description of the Invention As shown in Scheme I, following the general route developed by G. Bringmann et al., Angew. Chem. Int. Ed. Eng.. 25, 913 (1986) and G. Bringmann, et al., Liebigs Ann. Chem.. 877 (1993), the non-racemic tetrahydroisoquinoline 7 (I, Y=H, R,=R2=R3=R4=CH3), was prepared from methyl 3,5-dimethoxybenzoate (5) via Raney nickel reduction of the non-racemic α-methylbenzylimine 6, following the methodology of D.E. Nichols et al., 1 Med. Chem.. l&, 480 (1973). Demethylation of 7 with excess boron tribromide gave a diphenol amine»HBr salt, which was tribenzylated with benzyl bromide and cesium carbonate in DMF at room temperature (85%, two steps). Regiospecific iodination with iodine and silver sulfate gave C(5)-activated, benzyl protected 8 (66%), in accord with the methodology of W.W. Wy, Tetrahedron Lett.. 34, 6223 (1993). Likewise, direct bromination with Br2 yields the corresponding brominated compound.
Scheme I.
Figure imgf000008_0001
SBBSππiTE SHEET (Rffll 28 Generally, demethylation of 7 yields a compound of formula I wherein Y, R3 and R4 are H, and the hydroxyl groups can be reacted with other protecting groups, such as those disclosed hereinabove. Likewise, the iodo moiety can be replaced by Br or Cl by a variety of halogen exchange reactions, such as by lithiation, following reaction with elemental halogen. Replacement of (R)-PhCH (Me)NH2 with PhCH2NH2 and/or reaction with the corresponding 3,5-dimethoxyphenylacetaldehyde yields compounds of formula I wherein R1 and/or R2 is H. Synthesis of all the possible 1 ,3-isomers of 7, as well as compounds of formula 7 wherein one OMe group has been replaced by OH, is disclosed by G. Bringmann, et al., Liebigs Ann. Chem.. 877 (1993).
As shown in Scheme π, boronic acid 13 (II, R5=CH2OCH3, R7=CH3, R6=B(OH)2 was efficiently prepared from methoxymethyl (MOM)- protected 2,4-dibromophenol (9) by a regiospecific benzyne annulation reaction. Treatment of 9 with an excess of lithium cyclohexylisopropylamide and N,N- diethyl seneciamide, as disclosed by M. Watanabe et al., Chem. Pharm. Bull.. , 2810 (1986), gave 12 (II, R5=CH2OCH3, R7=CH3, R6=Br) presumably by way of benzyne 10 and lithium enolate 11. Although the yield of this reaction was only 29%, the transformation was very reproducible. O-Methylation with methylsulfate, lithiation, and boronic acid synthesis with B(OCH3)3 followed standard protocols to yield 13.
Reaction of a protected compound of formula II wherein R6=Li with Cl2 or I2 yields II, R6=C1 or I. Likewise, other acid-labile protecting groups can be used in place of MeOCH2 in compound 9, and R7=CH3 in formula II can readily be replaced with other protecting groups.
SβSπiϋlE SHEET (Mftf 28 Scheme II.
eOC
Figure imgf000010_0001
Figure imgf000010_0002
As shown in Figure 1, the palladium(O) catalyzed cross-coupling of 8 with 13 provided an about 4:3 ratio of the hindered atropisomers S-14 and R-14 (40-80%). Palladium(O) catalyzed cross-coupling is typically carried out in the presence of a base and an organic solvent. A preferred embodiment of the invention utilizes tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) as the source of palladium(O) catalyst, saturated sodium bicarbonate (NaHCO3) as the base and toluene as the organic solvent. Other useful sources of Pd(0) catalysts include those disclosed in Larock et al. (U.S. Patent No. 5,233,059, Col. 6) and Blaser et al. (U.S. Patent No. 4,335,054, Col. 6 and Col. 7), which may alternatively be used in the method of present invention under conditions wherein Pd(0) is generated. Bases useful in the present invention are those which are adequately soluble in the reaction medium. Although an inorganic base is preferred, an organic base can also be used. Representative bases are disclosed at Col. 7 of the Larock et al. patent, and Col. 7 of the Blaser et al. patent, as cited above. Examples of suitable organic solvents include, in addition to the preferred toluene, tetrahydrofuran, ethers, glycol ethers, dimethylsulfoxide, dimethyl forma ide, acetonitrile, acetamide, dimethylacetamide, and hexamethylphosphoramide.
Hydrolysis of the methoxymethyl (MOM) ethers of 14 gave the naphthols 15 (75-100%), which could be separated by careful normal-phase HPLC. Hydrogenolysis of the benzyl groups in a mixture of the naphthols 15 provided an about 4:3 mixture of korupensamine A and "C" atropisomers 4 and 4' . The mixture of tribenzylated naphthols 15 underwent remarkably efficient oxidative coupling with excess silver oxide in methylene chloride (or CDCI3) at room temperature by the methodology of H. Laatsch, Liebigs Ann. Chem.. 1321, (1980), to give the purple indigoids R,S-16, S,5-16, and R,R- 16 in an about 2:1:1 ratio (about 100%). The cross-ring quinones 16 could be reduced to the corresponding colorless binaphthols (sodium dithionite, H2O, CH2CI2 or NaBH4, CH2CI2, EtOH) and then perdebenzylated. More conveniently, direct exposure of 16 to one atmosphere of hydrogen in methylene chloride/methanol over 10% Pd/C resulted in simultaneous reductive bleaching of the indigoid and complete hydrogenolysis of the six benzyl groups.
Michellamines A-C were cleanly (as judged from the crude lH NMR spectrum) produced with nearly quantitative mass recovery. Separation of a small portion on amino-bonded phase [7:1 CH2Cl2:0.1 weight % (NH4)2CC>3 in methanol] has thus far provided a pure sample of michellamine A (1) along with an about 2: 1 mixture of michellamines B (2) and C (3), as determined by NMR analysis. The invention will further be described by reference to the following detailed examples.
Example 1. Preparation of If/?), 3(R)-l,2,3,4-tetrahydro-6,8- dihydroxy-l,3-dimethylisoquinoline hydrobromide salt (101)
Figure imgf000011_0001
( 1R, 3R)- 1 ,2,3,4-tetrahydro-6,8-dimethoxy- 1 ,3- dimethylisoquinoline was prepared as described in G. Bringmann et al., Liebigs Ann. Chem.. 877 (1993) and 50.7 mg (0.2 mmol) placed in an oven dried flask (5 mL r.b.) containing CH2CI2 (1 mL) and a magnetic stir bar. The flask was sealed with a rubber septum and the atmosphere was exchanged for nitrogen. The reaction mixture was cooled to -78 °C and a BBr3 solution (1 mL, 4.3 equiv, 1 M in CH2θ2) was added via syringe. The reaction mixture was immediately allowed to warm to room temperature and stir. After 10 h, the flask was cooled to -78 °C and carefully quenched with 1.5 mL of MeOH. The stir bar was removed and the reaction mixture was concentrated in vacuo to yield a brown oil.
"i , M MeOH (3.5 mL) was added to dissolve the oil and the reaction mixture was concentrated again. This quenching procedure was repeated 6-8 times until the hydrobromide salt 101 (62.8 mg, 100%) was isolated as brown crystals; lH NMR (500 MHz, CD3OD): δ 6.23 [d, J = 1.8 Hz, Ar-H(7)], 6.12 [d, J = 2.1 Hz, Ar-H(5)], 4.64 [q, J = 6.7 Hz, CH.CH3], 3.75 [ddq, J = 11.6, 4.6 and 6.5 Hz, CH2CHCH3], 2.98 [dd, J = 17.4 and 4.6 Hz, CHaxlieqCHCH3], 2.75 [dd, J = 17.4 and 11.6 Hz, CEaXHeqCHCH3], 1.59 [d, J = 7.0 Hz, CHCH3], and 1.46 [d, J = 6.4 Hz, CH2CHCH3]; *3C NMR (125 MHz, CD3OD): δ 158.97, 156.10, 133.65, 1 12.61, 107.01, 101.94, 49.35, 45.35, 34.59, 19.23, and 18.33; m.p. (range): 140-143 °; Anal. Calcd for C11H16NO2B1-: C, 48.19; H, 5.88. Found: C, 48.35; H, 5.69.
Example 2. Preparation of Tribenzylprotected Tetrahydroisoquinoline (102)
Figure imgf000012_0001
101 102
To a stirred solution of 1(R), 3(R)-l,2,3,4-tetrahydro-6,8- dihydroxy-l,3-dimethyl-isoquinoline hydrobromide salt (0.39 g, 1.4 mmol) in 15 mL of dry DMF was added benzylbromide ( 1.70 g, 10.0 mmol), followed by the addition of cesium carbonate (2.40 g, 7.4 mmol). After being stirred for 6 h at room temperature, the reaction mixture was poured into H2O (100 mL), and EtOAc (100 mL) was added. The organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by flash chromatography (hexanes/EtOAc Et3N; 9: 1:0.1) to yield tribenzyl-protected tetrahydroisoquinoline 102 (0.57 g, 86 %) as a thick yellow oil.; ^H NMR (500 MHz, CDCI3): δ 7.42-7.21 [m, benzyl ArH], 6.42 [d, J = 2.0 Hz, ArH(7)], 6.34 [d, J = 2.0 Hz, ArH(5)], 4.99 [s, O(6)CH2Ph], 4.98 [d, J = 12.0 Hz, O(8)CHaH Ph], 4.95 [d, J = 12.0 Hz, O(8)CHaiibPh], 4.01 [q, J = 7.0 Hz, ArCHCH3], 3.82 [d, J = 14.0 Hz, NCEaHbPh], 3.52 [ddq, J = 10.5, 4.5 and 6.5 Hz, CHaCH CH], 3.32 [d, J = 14.0 Hz, NCHaHjjPh], 2.63 [dd, J = 17.0 and 10.5 Hz, CHgCHbCH], 2.58 [dd, J = 17.0 and 4.5 Hz, CHaCHbCH], 1.34 [d, J = 6.5 Hz, CH3(1)], and 1.26 [d, J = 6.5 Hz. CH3(3)]; 13C NMR (75 MHz, CDCI3): δ 157.6, 157.1, 137.1, 136.7, 129.0, 128.7, 128.5 [5C], 128.4
SβBSTHϋTE SHEET ROLE 26 [2C], 128.3, 128.0 [2C], 127.9, 127.6 [2C], 126.9 [2C], 126.4, 105.5, 98.3, 70.0, 69.6, 51.2, 50.0, 45.7, 32.6, 19.9, and 19.5; IR (neat NaCl plates): 2967, 1603, 1454, and 1149 cπr1 ; Anal, calcd for C32H33NO2: C, 82.90; H, 7.17. Found: C, 82.89; H, 6.95.
Example 3. Preparation of Iodide (8)
Figure imgf000013_0001
102
A solution of compound 102 (0.48 g, 1.0 mmol) in 10 mL of
EtOH and 2 mL of CH2CI2 was added slowly to a stirred mixture of iodine (0.53 g, 2.1 mmol) and silver sulfate (0.69 g, 2.2 mmol) in 10 mL of EtOH. After being stirred at room temperature for 16 h, the yellow solid was removed by filtration and the filtrate was concentrated in vacuo. The resulting residue was dissolved in CH2CI2 ( 100 mL). This solution was washed with saturated
NaHCO3, H2O, dried over Na2SO4, and concentrated in vacuo. The residue was purified by flash chromatography (hexanes EtOAc; 9: 1) to yield iodide 8 (0.40 g, 66 %) as a thick oil; »H NMR (500 MHz, CDCI3): δ 7.49-7.18 [m, benzyl ArH], 6.41 [s, ArH(7)], 5.07 [s, O(6)CH2Ph], 4.98 [d, J = 12.0 Hz, O(8)CHaHbPh], 4.94 [d, J = 12.0 Hz, O(8)CHaIit>Ph], 4.01 [q, J = 6.5 Hz, CHCH3], 3.82 [d, J = 14.0 Hz, NCHaHbPh], 3.51 [ddq, J = 12.0, 4.0 and 6.5 Hz, CHaHbCHCH3], 3.20 [d, J = 14.0 Hz, NCHaHbPh], 2.66 [dd, J = 17.5 and 4.0 Hz, CHaHbCH], 2.42 [dd, J = 17.5 and 12.0 Hz, CHaCHb_CH], 1.34 [d, J = 6.5 Hz, CH3(1)], and 1.31 [d, J = 6.5 Hz, CH3(3)]; 13C NMR (75 MHz, CDCI3): δ 157.4, 156.1, 141.3, 139.5, 137.1 [2C], 128.9 [7C], 128.5 [2C], 128.2, 127.4 [2C], 127.2 [3C], 126.9, 124.3, 97.7, 71.6, 70.3, 51.9, 50.1, 46.9, 39.3, 20.2, and 20.1; IR (neat NaCl plates): 2971, 1585, 1324, and 1062 cm-1 ; Anal, calcd for C32H32INO2: C, 65.20; H, 5.47. Found: C, 65.39; H, 5.73. Example 4. Preparation of 5-Bromo-(lR, 3R)-l,2,3,4-tetrahydro- 6,8-dimethoxy-l,3-dimethylisoquinoline (103)
Figure imgf000014_0001
103
To a solution of tetrahydroisoquinoline 7 (50.0 mg, 0.23 mmol) in CH2C12 (0.5 ml) was added Br2 (13 μL, 0.25 mmol). After stirring for 10 min the reaction was diluted with Et2O, washed successively with with saturated K2CO3, saturated Na2S2θ3, and brine. The organics were then dried over 4 A molecular sieves, filtered, and concentrated in vacuo. The resulting residue was triturated with Et2O and a white solid was filtered (18.4 mg, 27% of brominated tetrahydroisoquinoline 103 as the HBr salt) The remaining material was purified by MPLC (hexanes EtOAc; 1:1 with 3% Et3N) to yield an additional quantity (39.4 mg, 57%) of the brominated species (84% total); *H NMR (200 MHz, CDCI3): δ 9.6 [vds, IH, NH], 6.39 [s, Ar-H(7)], 4.84 [q, J = 6.7 Hz, CHCH3], 3.88 [s, OMe], 3.85 [s, OMe], 3.73 [ddq, J = 11.6, 4.5, and 6.2 Hz, CH2CHCH3], 3.19 [dd, J = 17.7 and 4.5 Hz, CHaHbCHCH3], 2.92 [dd, J = 17.7 and 11.6 Hz, CHaHbCHCH3], 1.81 [d, J = 6.2 Hz, CH2CHCH3], and 1.70 [d, J = 6.7 Hz, CHCH3]; LRMS (El): m z 298 (MM, <1), 286 (97), 284 (100), 269, 256, 226, 204, 190, 176, 162, 147, 131 , 103, 91, 77, 51, and 42 (all <5).
Example 5. Preparation of N-benzyl-(lR, 3R)-l,2,3,4-tetrahydro- 6,8-dimethoxy-l,3-dimethylisoquinoline (104)
Figure imgf000014_0002
Into a stirred solution of (\R, 3/?)- l,2,3,4-tetrahydro-6,8- dimethoxy-l,3-dimethyl-isoquinoline (1 14 mg, 0.5 mmol) and benzyl chloride
:SKET BLE2 (137 mg, 1.1 mmol) in methyl ethyl ketone was added K2CO3 (320 mg, 2.3 mmol). The resulting mixture was heated to reflux for 24 h, after which time it was cooled down and poured into H2O. E_2θ was added and the organic layer was washed with H2O, brine, dried over MgSO4, and concentrated in vacuo. The crude product was purified by MPLC (hexanes EtOAc Et3N; 9: 1 :0.3) to yield N- benzyl-( 1 R, 3R)- 1 ,2,3 ,4-tetrahydro-6,8-dimethoxy- 1 ,3-dimethyl-isoquinoline (148 mg, 93 %) as a colorless oil; *H NMR (500 MHz, CDCI3): δ 7.40-7.20 [m, benzyl ArH], 6.28 [d, J = 2.0 Hz, ArH(7)], 6.23 [d, J = 2.0 Hz, ArH(5)], 3.66 [q, J = 6.5 Hz, ArCHCH3], 3.82 [d, J = 14.0 Hz, NCHaHbPh], 3.78 [s, O(6)CH3], 3.70 [s, O(8)CH3], 3.50 [ddq, J = 10.5, 5.0 and 6.5 Hz,
CHaHbCHCH3], 3.29 [d, J = 14.0 Hz, NCHaH_ϊ>Ph], 2.63 [dd, J = 17.0 and 10.5 Hz, CHaHbCH], 2.58 [dd, J = 17.0 and 5.0 Hz, CHaHjjCH], 1.30 [d, J = 6.5 Hz, CH3(1)], and 1.25 [d, J = 6.5 Hz, CH3(3)]; 13C NMR (75 MHz, CDCI3): δ 158.5, 158.4, 141.7, 136.8, 128.4 [2C], 128.1 [3C], 126.4, 104.1, 96.4, 55.2, 55.1, 51.4, 49.8, 45.8, 32.6, 20.0, and 19.5; LRMS (El): m/z 296 (M+-CH3, 100), and 91 (44); IR (neat NaCl plates): 2965, 1605, and 1148 cm"1; Anal, calcd for C20H25 O2: C, 77.14; H, 8.09. Found: C, 77.30; H, 8.06.
Example 6. Preparation of N-benzyl-(lR, 3_r?)-l,2,3,4-tetrahydro- 6,8-dihydroxy-l,3-dimethylisoquinoline hydrobromide salt (105)
Figure imgf000015_0001
Into a 15 mL culture tube was placed N-benzyl-(lR, 3R)- 1,2,3,4- tetrahydro-6,8-dimethoxy-l,3-dimethylisoquinoline (62 mg, 0.2 mmol) dissolved in acetic acid (1 mL). To this solution were added sodium iodide (120 mg, 0.8 mmol) and concentrated aqueous hydrobromic acid (49%, 2 mL). The mixture was heated at 100 °C for 3 hours and then cooled to 0 °C, at which time light yellow crystals precipitated out of solution. Vacuum filtration with a glass fritted Buchner funnel gave the N-benzyl-(lR, 3/?)-l,2,3,4-tetrahydro-6,8-dihydroxy- 1 ,3-dimethyl-isoquinoline hydrobromide salt [105] (48 mg, 66%) as light yellow crystals.
SBKTilrø SHEET røf 28 Example 7. Preparation of N-benzyl-(lR,3R)-5-bromo-l,2,3,4- tetrahydro-6,8-dimethoxy-l,3-dimethylisoquinoline (106)
Figure imgf000016_0001
104 106
Into a 25 mL round bottom flask was placed N-benzyl-(lR, 3R)- l,2,3,4-tetrahydro-6,8-dimethoxy-l,3-dimethylisoquιnoline (288 mg, 0.9 mmol) dissolved in methylene chloride (3 mL). Bromine ( 156 mg, 1.0 mmol) in methylene chloride (1 mL ) was added to the solution. The mixture was stirred for 3 h at room temperature and then diluted with methylene chloride (20mL) and washed with H2O (2 x 5 ml). The organic layer was dried with sodium sulfate and concentrated in vacuo to yield 360 mg of crude material. Separation on MPLC (hexane/ethyl acetate; 9:1, 3% Et3N) gave N-benzyl-( 1 R, 3R)-5-bromo- l,2,3,4-tetrahydro-6,8-dimethoxy-l,3-dimethylisoquinoline [106] (282 mg, 78%) as light yellow oil; 1H-NMR (CDCI3, 200 MHz): 57.31 [m, 5H, Ph], 6.4 [s, Ar-H(7)], 3.97 [q, J = 6.6 Hz, CKCH3], 3.91 [s, OMe] 3.84, [d, J = 14.4 Hz, CHcHdPh], 3.76 [s, OMe], 3.52 [ddq, J = 1 1.6, 6.0, and 4.6 Hz, CH2CHCH3], 3.19 [d, J = 14.4 Hz, CHcH Ph], 2.74 [dd, J = 17.7 and 4.6 Hz, CHaHbCHCH3], 2.45 [dd, J = 17.7 and 11.6 Hz, CHaHbCHCH3], 1.35 [d, J = 6.0 Hz, CH2CHCH3], and 1.31 [d, J = 6.6 Hz, CHCH3]; 13C-NMR (CDCI3, 200 MHz): δ 157.0, 154.4, 140.9, 136.1, 128.3 [2C], 128.0 [2C], 126.3, 122.1, 104.5, 94.3, 56.3, 55.3 [2C], 51.3, 49.4, 45.7, 33.1, and 19.8; LRMS (El): m/z 374 (MM5, 70), 360, 294, 268, 226, 203, 190, 162, 145 (all <5), 91 (100), 65, and 39.
Example 8. Preparation of Iodide (107)
Figure imgf000016_0002
SUBSTITUTE SECT ME 26 A solution of N-benzyl-(lR, 3R)-l,2,3,4-tetrahydro-6,8- dimethoxy-l,3-dimethyl-isoquinoline (198 mg, 0.61 mmol) in 5 mL of EtOH was added slowly to a stirred mixture of iodine (333 mg, 1.3 mmol) and silver sulfate (468 mg, 1.5 mmol) in lOmL of EtOH. After being stirred at room temperature overnight, the yellow solid was removed by filtration and the filtrate was concentrated in vacuo. The resulting residue was dissolved in 40 mL of CH2CI2. The solution was washed with saturated NaHCO3, H2O, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by flash chromatography (hexanes/EtOAc; 9: 1) to yield iodide 107 (200 mg, 75 %) as a white solid; *H NMR (500 MHz, CDCI3): δ 7.35-7.20 [m, 5H, Ph], 6.36 [s, ArH(7)], 3.90 [q, J = 6.5 Hz, ArCHCH3], 3.89 [s, O(6)CH3], 3.81 [d, J = 14.5 Hz, NCHaHbPh], 3.75 [s, O(8)CH3], 3.49 [ddq, J = 11.5, 4.5 and 6.5 Hz, CHaHbCHCH3], 3.16 [d, J = 14.5 Hz, NCHaHfcPh], 2.63 [dd, J = 17.5 and 4.5 Hz, CH^CH], 2.39 [dd, J = 17.5 and 11.5 Hz, CHatfeCH], 1.33 [d, J = 6.5 Hz, CH3(1)], and 1.29 [d, J = 6.5 Hz, CH3(3)]; 13C NMR (75 MHz, CDCI3): δ 158.5, 156.8, 141.1, 139.1, 128.4 [2C], 128.1 [3C], 126.4, 123.2, 94.0, 56.6, 55.3, 51.7, 49.6, 46.6, 38.7, 19.9, and 19.8; IR (neat NaCl plates): 2966, 1586, 1453, 1326, 1207, and 1072 cm-1.
Example 9. Preparation of 2,4-Dibromo-l-methoxymethoxybenzene
(9)
Figure imgf000017_0001
Into a 500-mL round bottom flask equipped with a soxlet and a condensor were placed 2,4-dibromophenol (32.0 g, 0.13 mole), dimethoxymethane (200 mL, 2.26 mole), p-toluenesulfonic acid monohydrate (2.24 g, 12.0 mmol) and CH2CI2 (200 mL). The soxlet extractor was filled with 3 A and 4 A molecular sieves. The reaction mixture was heated to reflux for 24 h after which time the soxlet extractor was filled with freshly activated sieves. The reaction mixture was heated to reflux for another 24 h. After this period of time, Et3N (10 mL) was added. The reaction mixture was stirred for 5 min, and
SBsπππE concentrated to dryness. The residue was dissolved in CH2C12 (400 mL) and the resulting solution was washed with 5 % NaOH (400 mL), H2O (400 mL), dried over Na2SO4, and concentrated in vacuo. The crude product was purified by flash chromatography (hexanes EtOAc; 6:1) to yield 2,4-Dibromo-l- methoxymethoxybenzene [9] (32.9 g, 88 %) as a light yellow oil; Η NMR (CDC13, 300 MHz) δ 7.67 [s, ArH(3)], 7.33 [d, J = 8.7 Hz, ArH(5)], 7.02 [d, J = 8.7 Hz, ArH(6)], 5.21 [s, OCH2OCH3], and 3.49 [s, OCH3]; LRMS (El) m/z 298 (M+, 3), 296 (M+, 5), 294 (M+, 3), and 45 (100).
Example 10. Preparation of Naphthol (12)
Figure imgf000018_0001
To a stirred solution of isopropylcyclohexylamine (7.5 mL, 0.45 mmol) in 60 mL of THF at -78 °C under N2 was added n-BuLi (20.0 mL, 50.0 mmol, 2.5 M in hexanes). The mixture was stirred for 20 min, warmed to 0 °C, and then stirred for 1 h. The mixture was cooled to -78 °C and solution of N,N- diethyl-3,3-dimethylacrylamide (2.10 g, 13.0 mmol) in 40 mL of THF was added. This mixture was stirred at -78 °C for 1 h. The cold bath was removed and the reaction mixture was allowed to warm to -20 °C over a period of 10 min. A solution of 2,4-dibromo-l -methoxymethoxybenzene (9) in 30 mL of THF was added. The reaction mixture was stirred overnight at room temperature, and then quenched with saturated NH4CI. Et2O was added and the solution was washed with H2O, brine, dried over Na2SO4, and concentrated in vacuo.The crude product was purified by flash chromatography (hexanes/EtOAc; 9: 1 ) to yield napthol 12 (1.15 g, 29 %) as a brown oil; *H NMR (CDCI3, 300 MHz): δ 9.31 [s, OH], 7.54 [d, J = 8.4 Hz, ArH(6)], 7.49 [s, ArH(4)], 6.82 [s, ArH(2)], 6.81 [d, J = 8.4 Hz, ArH(7)], 5.46 [s, OCH2OCH3], 3.55 [s, OCH3], and 2.47 [s, ArCH3(3)]; 13C NMR (CDCI3, 75 MHz): δ 154.3, 153.5, 139.5, 134.5, 129.6, 118.2, 115.5, 1 14.5, 113.6, 107.3, 95.9, 56.9, and 22.0; LRMS (El): m/z 298 (M+,13), 296 (M+, 11), 128 (5), 115 (9). and 45 (100).
JDWTTDTE SHEET ROE Example 11. Preparation of Bromide (111)
Figure imgf000019_0001
To a stirred solution of dimethyl sulfate (2.49 g, 20.0 mmol) in 20 mL of CH2C12 was added a solution of Bu4NBr (2.19 g, 6.8 mmol) and NaOH (0.50 g, 12.0 mmol) in 15 mL of H2O and a solution of naphthol 12 (1.07 g, 3.6 mmol) in 10 mL of CH2C12. The reaction mixture was stirred at room temperature for 18 h. The organic and aqueous layers were separated and the aqueous layer was extracted with 20 mL of CH2C12. The combined organic layers were washed with H2O, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by MPLC (hexanes EtOAc; 9:1) to yield 111 (0.83 g, 74 %) of as a white solid; *H NMR (CDC13, 300 MHz): δ 7.63 [s, ArH(5)], 7.62 [d, J = 8.1 Hz, ArH(3)], 6.86 [d, J = 8.1 Hz, ArH(2)], 6.75 [s, ArH(7)], 5.22 [s, OCH2OCH3], 3.94 [s, ArO(8)CH3], 3.58 [s, OOfcOCHaJ, and 2.51 [s, ArCH3(6)]; 13C NMR (CDCI3, 75 MHz): δ 156.8, 154.0, 137.8, 135.0, 130.4, 119.5, 118.1, 115.3, 112.9, 109.3, 96.8, 56.5, 56.4, and 22.2; LRMS (El): m/z 312 (M+, 18), 310 (M+ 19), 282 (15), 280 (16), 231 (2), 128 (14), and 45(100).
Example 12. Preparation of Compound (113)
Figure imgf000019_0002
In a 250 mL round bottomed flask a solution of lithiumisopropylcyclohexylamide was prepared from isopropylcyclohexylamine (6.21 g, 7.23 mL, 44 mmol) in THF (50 mL) and butyllithium (2.5 M in hexane, 17.6 mL, 44 mmol). The solution was cooled to - 78 °C under nitrogen and N,N-
s diethyl-3,3-dimethylacrylamide [109] (3.10 g, 20 mmol) in THF (20 mL) was added. After stirring for 30 min at - 78 °C, the solution was warmed to room temperature and stirred for 5 h. The reaction mixture was then cooled to - 78 °C, and 1 ,4-dibromoanisole [112] (5.852 g, 22 mmol) in THF (30 mL) was added via syringe. The solution was stirred at 0 °C for 24 h and then quenched with saturated aqueous ammonium chloride (100 mL) and diluted with ether (30 mL). The organic layer was separated and the aqueous layer was extracted with ether (3 x 40 mL). The combined organic layers were washed with brine (40 mL), dried with sodium sulfate and concentrated in vacuo to give 4.60 g of crude material. Flash chromatography of the crude material (hexane/ethyl acetate; 9: 1) yielded product 113 (1.17 g, 22%) as a light yellow oil.
Example 13. Preparation of Compound (114)
Figure imgf000020_0001
113 114
A solution of dimethyl sulfate (2.52 g, 20.0 mmol) in methylene chloride (20 mL) was prepared in a 100 mL round bottom flask. To the flask was added a solution of tetrabutyl-ammonium bromide (2.25 g, 7.0 mmol) and sodium hydroxide (400 mg, 10.0 mmol) in water (15 mL). To this mixture was added a solution of compound 113 (1.335 g, 5 mmol) in methylene chloride (10 mL). The reaction mixture was stirred at room temperature for 18 h and then diluted with methylene chloride (20 mL). The organic and aqueous layers were separated, and the aqueous layer was extracted with of methylene chloride (20 mL). The combined organic layers were washed with water (10 mL), dried with sodium sulfate, and concentrated in vacuo. The resulting residue was purified by flash chromatography (hexane/ethyl acetate; 9: 1 ) to obtain compound 114 ( 1.32 g, 94%) as a white solid.
SβSTmJTE S Example 14. Preparation of Compound (116)
Figure imgf000021_0001
115 116
In a 100 mL round bottom flask, 7-methyl-Juglone [115] (242.4 mg, 1.2 mmol) was dissolved in chloroform (30 mL). Water (15 mL) and sodium dithionite (627 mg, 3.6 mmol) were added to this and the mixture was stirred at room temperature for 1 h. When TLC analysis showed no starting material remaining, the organic layer was separated, washed with brine, dried with sodium sulfate and concentrated in vacuo to yield compound 116 (245 mg, 100%) as a white solid.
Example 15. Preparation of Compound (117)
Figure imgf000021_0002
Compound 116 (204 mg, 1.0 mmol) was placed in a 50 mL round bottom flask with methylene chloride (10 mL ) and pyridine (0.32 mL, 4.0 mmol). The mixture was cooled to - 5 °C and triflic anhydride (0.20 mL, 1.15 mmol) was added. The reaction mixture was stirred at room temperature for 12 h.
Methylene chloride (20 mL) was added and the mixture was washed with water, dried with sodium sulfate and concentrated in vacuo. Purification by flash chromatography (Hexanes/ethyl acetate; 12:1) yielded product 117 (182 mg,
54%) as a white solid. Example 16. Preparation of Compound (118)
Figure imgf000022_0001
Into a 15 mL round bottom flask was placed monotriflate 117 (50 mg, 0.15 mmol) dissolved in methylene chloride (2 mL ). To this solution was added acetic anhydride (0.04 mL, 0.45 mmol) and pyridine (0.072 mL, 0.90 mmol). The reaction mixture was stirred at room temperature for 9 h. When TLC analysis showed no remaining starting material, the mixture was diluted with methylene chloride (10 mL), washed with water, dried with sodium sulfate and concentrated in vacuo to give compound 118 (56 mg, 100%) as a white solid.
Example 17. Preparation of Boronic Acid (13)
Figure imgf000022_0002
To a stirred solution of 111 (0.83 g, 2.7 mmol) in 30 mL of THF at -78 °C under N2 was added n-BuLi (1.3 mL, 3.2 mmol, 2.5 M in hexanes). The resulting mixture was stirred for 15 min and then cannulated into a solution of B(OMe)3 (0.65 mL, 5.7 mmol) in 30 mL of THF. The reaction mixture was stirred for another 15 min, then warmed to room temperature and stirred for 2 h. The reaction mixture was quenched with 10 % HCI, diluted with Et2O, washed with H2O, brine, dried over MgSO4, and concentrated in vacuo to yield boronic acid 13 (0.74 g, 100 %) as a brown solid. This compound was used without further purification. The structure of boronic acid [13] was confirmed by derivatization to boronate ester 119; GC: t = 13.3 min; column: DB-5, 6 m x
Figure imgf000022_0003
O.l mm x O.l μm film; temp prom: 50 °C / 2 min / 20 °C min"1 / 250 °C / 10 min; LRMS (El): m/z 344 (M+, 100), 314 (46), 300 (20), 270 (17), and 45 (75).
Example 18. Preparation of Boronic Anhydride (120)
120
Into a 25 mL flame dried flask was placed bromide 111 (1.10 g, 3.54 mmol) freshly distilled THF (10 mL). Under nitrogen, the solution was cooled to - 78 °C and then n-butyllithium (2.5 M in hexane, 1.7 mL, 4.2 mmol) was added. The resulting solution was stirred for 15 minutes, after which time a precipitate appeared. Trimethyl borate (1.7 mL, 14.4 mmol) was added to the flask and a clear solution formed. The mixture was stirred at - 78 °C for 30 min and then at room temperature for 2 h. The mixture was quenched with saturated aqueous ammonium chloride (10 mL), concentrated, and diluted with of methylene chloride (20 mL). The organic and aqueous layers were separated and the aqueous layer was neutralized with 10% aqueous hydrochloric acid. The aqueous layer was extracted with methylene chloride (2 x 20 mL), and the combined organics were washed with H2O (10 mL) and dried over sodium sulfate. Concentration in vacuo yielded 1.0 g of crude material as a caramel colored residue. Precipitation from methylene chloride by addition of hexanes gave the anhydride 120 (548 mg, 60%) as a white solid; 1H-NMR (CDCI3, 300 MHz): δ 8.72 [s, ArH(l)], 8.52 [s, J = 7.7 Hz, ArH(7)], 7.08 [d, J = 7.8 Hz, ArH(6)], 6.76 [s, ArH(3)], 5.37 [s, OCJkOCHs], 3.97 [s,ArOCH3], 3.62 [s, OCH2OCU3J, and 2.43 [s, ArCH3].
Example 19. General Procedure for the PaIladium(0)-Mediated Biaryl Coupling Reactions
To a stirred solution of aryl iodide in toluene (0.05 M) was added
2 equivalents of boronic acid (or its derivatives). Saturated NaHCO3 (1/2 volume
SWSπT TE of toluene) was then added, followed by the addition of 20 mol % of Pd(PPh3)4. The reaction mixture was sealed under N2 in a culture tube and heated to 110 °C for 20 h. After this period of time, EtOAc and brine were added. The organic layer was extracted, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel chromatography.
A. Preparation of Compound (14)
Figure imgf000024_0001
13 8 S-14 R-14
Compound 14 was obtained from boronic acid 13 and iodide 8 in 81% yield with a 4:3 ratio of S-14 to R-14. The product was purified by MPLC (hexanes/EtOAc/Et3N; 3:1:0.1); ifi. NMR of S-14 (500 MHz, CDC13): δ 7.39- 6.90 [m, ArH(6' and 7') and benzyl ArH], 6.77 [s, ArH(l')], 6.69 [s, ArH(3')], 6.53 [s, ArH(7)], 5.31 [s, OCH2OCH3], 5.02 [s, O(6)CH2Ph], 4.87 [d, J = 12.5 Hz, O(8)CHaHbPh], 4.81 [d, J = 12.5 Hz, O(8)CHaHb.Ph], 4.12 [q, J = 6.5 Hz, PhCHCH3], 3.98 [s, O(4')CH3], 3.72 [d, J = 14.5 Hz, NCHaHbPh], 3.65 [s, OCH2OCH.3 , 3.37 [ddq, J = 11.5, 4.0, and 6.5 Hz, CHaHbCHCH3], 3.30 [d, J = 14.5 Hz, NCHaHbPh], 2.36 [s, CH3(2')], 2.22 [dd, J = 17.5 and 4.0 Hz, CHaHbCH], 2.00 [dd, J = 17.5 and 11.5 Hz. CHaHbCH], 1.41 [d, J = 6.5 Hz, CH3(1)], and 1.01 [d, J = 6.5 Hz, CH3(3)]; lH NMR of R-14 (500 MHz, CDCI3): δ 7.39-6.90 [m, ArH(6' and 7') and benzyl ArH], 6.86 [s, ArH(l')], 6.70 [s, ArH(3')], 6.51 [s, ArH(7)], 5.31 [s, OCH2OCH3], 5.03 [d, J = 12.0 Hz, O(6)CH HbPh], 4.97 [d, J = 12.0 Hz,
Figure imgf000024_0002
4.86 [d, J = 12.5 Hz, O(8)CHaHbPh], 4.81 [d, J = 12.5 Hz, O(8)CHaHbPh], 4.11 [q, J = 6.5 Hz, PhCHCH3], 3.98 [s, O(4')CH3], 3.77 [d, J = 14.5 Hz, NCHaHbPh], 3.65 [s, OCH2OCH3_L 3.37 [ddq, J = 14.0, 4.0, and 6.5 Hz, CHaHbCHCH3], 3.35 [d, J = 14.0 Hz, NCHaHbPh], 2.36 [s, CH3(2')], 2.25 [dd, J = 17.0 and 14.0 Hz, CHaHbCH], 1.92 [dd, J = 17.0 and 4.0 Hz. CH^CH], 1.39 [d, J = 6.5 Hz, CH3(1)], and 1.05 [d, J = 6.5 Hz, CH3(3)]; IR (neat NaCl plates): 2967, 1584, 1052, and 733 cm"1. B. Preparation of Compound (121)
Figure imgf000025_0001
120 107 121a 121b
Into a 15 mL culture tube were placed N-benzyl-(lR, 3R)-5-iodo- l,2,3,4-tetrahydro-6,8-dimethoxy-l,3-dimethylisoquinoline [107] (66 mg, 0.15 mmol) and toluene (3 mL). To this solution was added compound 120 (58 mg, 0.23 mmol), which resulted in the formation of a slurry. A minimum amount of ethanol was added to change the slurry to a clear solution. To the resulting solution was added tetrakis(triphenylphosphine)palladium(0) ( 17 mg, 0.015 mmol) and saturated aqueous sodium bicarbonate (1.5 mL). The atmosphere was exchanged for N2 and me reaction mixture was heated at 110 °C for 12 hours. When TLC showed no substrate boronate left, the organic and aqueous layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 5 mL). The combined organics were washed with brine, dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (hexane/ethyl acetate ; 9:1, 3% Et3N) to yield a mixture of compounds 121a and 121b (50 mg, 60%) as a white solid; *H NMR of 121a (500 MHz, CDC13): δ 7.39-7.21 [m, benzyl ArH], 7.17 [d, J = 8.0 Hz, ArH(7')], 7.07 [d, J = 7.5 Hz, ArH(6')], 6.74 [s, ArH(l')], 6.68 [s, ArH(3')], 6.49 [s, ArH(7)], 5.31 [s, OCH2OCH3], 4.00 [q, J = 6.5 Hz, NCJICH3], 3.97 [s, O(4')CH3], 3.85 [s, O(6)CH3], 3.72 [d, J = 14.5, NCHfiHbPh], 3.65 [s, O(8)CH3], 3.64 [s, OCH2O£H3_], 3.36 [ddq, J = 11.0, 6.5 and 4.0 Hz, CHaHbCϋCH3], 3.26 [d, J = 14.0 Hz, NCHaHb_Ph], 2.35 [s, CH3(2')], 2.12 [dd, J = 17.5 and 4.0 Hz, CHa.HbCH], 1.94 [dd, J = 17.5 and 11.0 Hz,
CHaHbCH], 1.38 [d, J = 7.0 Hz, CH3(1)], 1.00 [d, J = 6.5 Hz, CH3(3)]; *H NMR of 121b (500 MHz, CDCL3): δ 7.39-7.21 [m, benzyl ArH], 7.12 [d, J =
8.0 Hz, ArH(7')], 7.06 [d, J = 8.0 Hz, ArH(6')], 6.79 [s, ArH(l')], 6.69 [s, ArH(3')], 6.48 [s, ArH(7)], 5.30 [s, OCH2OCH3], 4.01 [q, J = 6.5 Hz, N£HCH3], 3.97[s, O(4')CH3], 3.84 [s, O(6)CH3], 3.76 [d, J = 14.0 Hz, NCHaHbPh], 3.65 [s, O(8)CH3], 3.62 [s, OCH2OCU2], 3.36 [ddq, J = 12.0, 6.5 and 4.5 Hz, CHaHb£HCH3], 3.31 [d, J = 14.5 Hz, NCHaHbPh], 2.35 [s,
SWST CH3(2')], 2.17 [dd, J = 18.0 and 12.0 Hz, CHaH CH], 1.82 [dd, J = 17.5 and 4.5 Hz, CHaCHbCH], 1.38 [d, J = 7.0 Hz, CH3O)], 1.03 [d J = 6.5 Hz, CH3(3)].
Example 20. General Procedure for the Hydrolysis Reactions
To a stirred solution of methoxy methyl -protected starting material in a mixed solvent (MeOH/CH Cl2-10: l, 0.01 M) was added 10 N HCI (1/20 volume of solvent). The reaction mixture was stirred at room temperature for 16 h. After this period of time the solvent was evaporated. EtOAc and saturated NaHCO3 were added. The organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by chromatography .
A. Preparation of Compound (15)
Figure imgf000026_0001
Compound 15 was obtained from compound 14 in 71 % yield.
The product was purified by MPLC (hexanes/EtOAc Et3N; 3: 1:0.1); lH NMR of S-15 (500 MHz, CDCI3): δ 9.40 [s, OH], 7.39-6.95 [m, ArH(7') and benzyl ArH], 6.91 [d, J = 8.0 Hz, ArH(6')], 6.76 [s, ArH( l')], 6.62 [s, ArH(3')], 6.52 [s, ArH(7)], 5.01 [s, O(6)CH2Ph], 4.88 [d, J = 13.0 Hz, O(8)CHaHbPh], 4.82 [d, J = 13.0 Hz, O(8)CHaHbPh], 4.08 [q, PhCHCH3, hidden by O(4')CH3], 4.08 [s, O(4')CH3], 3.72 [d, J = 14.0 Hz, NCHaHbPh], 3.37 [ddq, J = 1 1.5, 4.0, and 6.5 Hz, CHaHbCHCH3], 3.29 [d, J = 14.0 Hz, NCHaHbPh], 2.36 [s, CH3(2')], 2.21 [dd, J = 17.5 and 4.0 Hz, CHaHbCH], 1.90 [dd, J = 17.5 and 11.5 Hz, CHaHbCH], 1.40 [d, J = 6.5 Hz, CH3(1)], and 1.01 [d, J = 6.5 Hz, CH3(3)]; !H NMR of R-15 (500 MHz, CDCI3): 6 9.42 [s, OH], 7.39-6.95 [m, ArH(7*) and benzyl ArH], 6.90 [d, J = 8.0 Hz, ArH(6')], 6.85 [s, ArH(l')], 6.63 [s, ArH(3')], 6.50 [s, ArH(7)], 5.03 [d, J = 1 1.5 Hz, O(6)CHaHbPh], 4.97
SSSSfMTE SHEET (RMi 26) [d, J = 11.5 Hz, O(6)CHaHb_Ph], 4.87 [d, J = 13.0 Hz, O(8)CH .HbPh], 4.82 [d, J = 13.0 Hz, O(8)CHaHb_Ph], 4.08 [q, PhCHCH3, hidden by O(4')CH3], 4.08 [s, O(4')CH3], 3.77 [d, J = 14.0 Hz, NCHaHbPh], 3.37 [ddq, J = 11.5, 4.0, and 6.5 Hz, CHaHbCHCH3], 3.34 [d, J = 14.0 Hz, NCHaHfcPh], 2.36 [s, CH3(2')], 2.24 [dd, J = 17.5 and 11.5 Hz, CH HbCH], 1.90 [dd, J = 17.5 and 4.0 Hz, CHaHb.CH], 1.38 [d, J = 6.5 Hz, CH3(1)], and 1.05 [d, J = 6.5 Hz, CH3(3)].
B. Preparation of Compound (122)
Figure imgf000027_0001
121a 121b 122a 122b
In a 10 mL round bottom flask, a mixture of substrates 121a and 121b (11 mg, 0.02 mmol) was dissolved in methanol (3 mL). To the solution was added 10% aqueous HCI (2 mL) and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated in vacuo and the resulting residue was dissolved in ethyl acetate (10 mL ), washed with sodium bicarbonate, water, and dried over sodium sulfate. Concentration in vacuo yielded a mixture of compounds 122a and 122b (10 mg, 100%) as a white solid.
Example 21. General Procedure for the Per-debenzylation
Reactions
To a solution of benzyl-protected monomer in a mixed solvent
(MeOH/CH2Cl2-2:l, 0.01 M) was added 10 % Pd C (20 mol %). The atmosphere was exchanged for N2, then H , and then a H2 balloon was attached.
The reaction mixture was stirred until TLC analysis indicated no starting material and possible intermediate left. The catalyst was removed by passing through a bed of Celite. The filtrate was concentrated in vacuo to yield deprotected monomer.
The mixture of atropisomers was able to be separated by HPLC using an amino- bonded column. A. Preparation of Korupensamine A & "C"
Figure imgf000028_0001
Compound 4 and 4* were obtained from compounds 15 in 75 % yield. The atropisomers Korupensamine A [4] and "Korupensamine C" [4'] were separated by HPLC using an amino-bonded column (CHCl3/MeOH/(NH4)2CO3; 95:5:0.1); *H NMR of 4 (HOAc Salt) (500 MHz, CD3OD, referenced to CHD2OD @ 3.30 ppm): δ 7.09 [d, J = 8.0 Hz, ArH(7')], 6.80 [d, J = 8.0 Hz, ArH(6')], 6.78 [s, AτH(3')], 6.69 [s, Ar(l')], 6.44 [s, ArH(7)], 4.75 [q, J = 7.0 Hz, ArCHCH3], 4.08 [s, O(4')CH3], 3.65 [ddq, J = 12.0, 5.0 and 6.5 Hz, CHaHbCHCH3], 2.62 [dd, J = 18.0 and 5.0 Hz, CHaHbCH], 2.30 [s, CH3(2')], 2.05 [dd, J = 18.0 and 12.0 Hz, CHaHbCH], 1.64 [d, J = 7.0 Hz, CH3(1)], and 1.19 [d, J = 6.5 Hz, CH3(3)]; *H NMR of 4' (HOAc Salt) (500 MHz, CD3OD, referenced to CHD2OD @ 3.30 ppm): δ 7.02 [d, J = 8.0 Hz, ArH(7')], 6.80 [d, J = 8.0 Hz, ArH(6')L 6.80 [s, ArH(l' or 3')], 6.78 [s, Ar(3" or 1')], 6.44 [s, ArH(7)], 4.74 [q, J = 7.0 Hz, ArCHCH3], 4.08 [s, O(4')CH3], 3.62 [ddq, J = 12.0, 5.0 and 6.5 Hz, CHaHbCHCH3], 2.38 [dd, J = 18.0 and 12.0 Hz, CHaHbCH], 2.33 [s, CH3(2")], 2.23 [dd, J = 18.0 and 5.0 Hz, CH^CH], 1.67 [d, J = 6.5 Hz, CH3(1)], and 1.23 [d, J = 6.5 Hz, CH3(3)].
Example 22. General Procedure for the Silver Oxide Promoted Oxidative Coupling and Simultaneous Reductive Bleaching/Per- debenzylation Reactions
To a stirred solution of benzyl-protected monomer in CH2C12 (0.01 M) was added 5 equivalent of Ag2O. The reaction mixture was stirred at room temperature in the dark for 40 h. The solid was removed by passing through the Celite bed. MeOH (volume equal to that of CH2C12) was added to the filtrate, followed by the addition of 10 % Pd/C (20 mol %). The atmosphere was exchanged for N2, then H ι and then a H balloon was attached. The reaction mixture was stirred until TLC analysis indicated no starting material and possible intermediate left. The catalyst was removed by passing through a bed of Celite. The filtrate was concentrated to yield deprotected dimer. The crude product was further purified by HPLC with amino-bonded column.
A. Preparation of Michellamines A, B, and C
Figure imgf000029_0001
LAg jO r 2. H2, Pd/C " 3. HPLC
Figure imgf000029_0002
Michellamines A-C [1-3] were obtained from compound 15 in 90 % yield. They were separated by HPLC using an amino-bonded column (CHCl3/MeOH/(NH4)2CO3; 93:7:0.1); *H NMR of Michellamine A (1, HOAc Salt) (500 MHz, CD3OD, referenced to CHD2OD @ 3.30 ppm): δ 7.30 [s, ArH(7')], 6.85 [s, ArH(3')], 6.74 [s, ArH(l')], 6.44 [s, ArH(7)], 4.77 [q, J = 7.0 Hz, ArCHCH3], 4.10 [s, O(4')CH3], 3.70 [ddq, J = 12.0, 4.5 and 6.5 Hz, CHaHbCHCH3], 2.82 [dd, J = 18.0 and 4.5 Hz, CHaHbCH], 2.34 [s, CH3(2')], 2.15 [dd, J = 18.0 and 12.0 Hz, CHaHhCH], 1.65 [d, J = 6.5 Hz, CH3(1)], and 1.24 [d, J = 6.5 Hz, CH3(3)]; *H NMR of Michellamine B (2, HOAc Salt) (500 MHz, CD3OD, referenced to CHD2OD @ 3.30 ppm): δ 7.32/7.27 [s, ArH(7')],
6.86/6.74 [s, ArH(3')], 6.85/6.83 [s, ArH(l')], 6.45 [s, ArH(7)], 4.76/4.73 [q, J = 7.0/7.0 Hz, ArCHCH3], 4.10/4.09 [s, O(4')CH3], 3.73-3.62 [m, CHaHbCHCH3], 2.79 [dd, J = 17.5 and 5.0 Hz, CHaHbCH], 2.53 [dd, J = 18.0 and 1 1.5 Hz, CHaHfcCH], 2.36/2.33 [s, CH3(2')], 2.34-2.29 [dd, CHaHbCH, hidden by CH3(2')], 2.12 [dd, J = 18.0 and 11.5 Hz, CHaHbCH], 1.69/1.64 [d, J = 6.5/7.0 Hz, CH3(1)], and 1.26/1.22 [d, J = 6.0/6.5 Hz, CH3(3)].
B. Preparation of Compounds (123a), (123b), and (123c)
Figure imgf000030_0001
LAg- 2. NaBH4
Figure imgf000030_0002
In a 10 mL round bottom flask, substrates 122a and 122b (5 mg, 0.01 mmol) were dissolved in methylene chloride (3 mL). To the solution was added silver (I) oxide (7 mg, 0.03 mmol) and the mixture was stirred at room temperature overnight. When TLC analysis showed no starting materials were left, the mixture was filtered through a bed of Celite bed. Concentration of the filtrate gave a blue solid (5 mg, 100%) which was dissolved in a mixed solvent of methylene chloride (2 mL) and methanol (2 mL). To the mixture was added a solution of NaBH4 in methanol (2 mL). The mixture was concentrated, and the residue was dissolved in methylene chloride (10 mL), washed with water, and dried over sodium sulfate. Concentration in vacuo yielded a mixture of compounds 123a, 123b, and 123c (5 mg, 100%) as a white solid. It will be appreciated by those skilled in the art that various modifications can be made to the above described embodiments of the invention without departing from the essential nature thereof. The invention is intended to encompass all such modifications within the scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula (I):
Figure imgf000032_0001
wherein X is Br, Cl or I, Y is H, (C,-C4)alkyl, benzyl, or CHO, each of R1 and R2 is H or CH3, R3 is H or (C2-C5)acyl and R4 is a protecting group selected from the group consisting of (C,-C4)alkyl, benzyl, (C2-C5)acyl and an acid-labile hydroxy protecting group.
2. The compound of claim 1 wherein R4 is an acid-labile hydroxy protecting group.
3. The compound of claim 2 wherein the acid labile protecting group is (C,-C4)alkoxy(C,-C4)alkyl, tetrahydropyranyl, or (R8)3Si, wherein each
R8 is (C,-C4)alkyl.
4. The compound of claim 1 wherein R1 and R2 are CH3.
5. The compound of claim 4 wherein C, and C3 have the R configuration.
6. The compound of claim 4 wherein X=I.
7. A compound of the formula (I):
2
Figure imgf000033_0001
wherein X is Br, Cl or I, Y is H, (CrC4)alkyl, benzyl, or CHO, each of R1 and R2 is H or CH3, R3 is a protecting group selected from the group consisting of (C,-C4)alkyl, benzyl, (C2-C5)acyl and an acid-labile hydroxy protecting group; and R4 is H or (C2-C5)acyl.
8. The compound of claim 7 wherein R3 is an acid-labile hydroxy protecting group.
9. The compound of claim 8 wherein the acid labile protecting group is (C|-C4)alkoxy(CrC4)alkyl, tetrahydropyranyl, or (R8)3Si, wherein each
R8 is (C,-C4)alkyl.
10. The compound of claim 7 wherein R1 and R2 are CH3.
11. The compound of claim 10 wherein C, and C3 have the R configuration.
12. The compound of claim 10 wherein X=I.
13. A compound of the formula (II):
Figure imgf000034_0001
wherein R6 is Cl, Br, I, B(OH)2, an anhydride or ester of B(OH)2, or OSO2R9, wherein R9 is (C,-C4)perfluoroalkyl. and each of R5 and R7 is H, (C,-C4)alkyl, benzyl, (C2-C5)acyl or an acid-labile hydroxy protecting group.
14. The compound of claim 13 wherein R6 is Br or B(OH)2, R5 is an acid-labile protecting group, and R7 is H or CH3.
15. A method of preparing a korupensamine or an analog thereof comprising: (a) reacting a compound of the formula (III):
Figure imgf000034_0002
wherein each of R1 and R2 is CH3 or H, X is I, Y is (C,-C4)alkyl, benzyl or CHO, and each of R3 and R4 is (C,-C4)alkyl. benzyl, (C2-C5)acyl or an acid-labile hydroxy protecting group: with a compound of the formula (IV):
Figure imgf000035_0001
wherein Rs is benzyl, (C2-C5)acyl or an acid-labile hydroxy protecting group, R6 is B(OH)2, and R7 is (C,-C4)alkyl; in the presence of a Pd(0) catalyst and an inorganic base in an organic solvent, to yield a compound of the formula (V):
Figure imgf000035_0002
wherein Y, R1, R2, R3, R4, R5 and R7 are as defined above for compounds of formula III and IV.
16. The method of claim 15 further comprising (b) removing protecting groups R3, R4, R5 and Y to yield a compound of formula V wherein each of R1 and R2 is H or CH3, R7 is (C,-C4)alkyl, and Y, R2, R\ R4, and R5 are H.
17. The method of claim 16 wherein C, and C3 have the R configuration.
18. The method of claim 17 wherein the korupensamine prepared is korupensamine A or korupensamine B.
19. The method of claim 15 wherein R1, R2 and R7 are CH3, R5 is an acid-labile hydroxy protecting group that is subsequently removed by exposing V to dilute aqueous acid, and Y, R3 and R4 are benzyl that are subsequently removed by hydrogenolysis.
20. The method of claim 19 wherein R5 is methoxymethyl.
21. The method of claim 15 wherein C, and C3 have the R configuration, R\ R2 and R7 are CH3, Y,R3 and R4 are benzyl, and R5 is an acid-labile hydroxy protecting group, further comprising (b) removing the acid-labile hydroxy protecting group by exposing V to dilute acid and (c) oxidatively coupling two molecules of V to yield 5,5-16, R,5-16 and R R-16 as shown in Fig. 1.
22. The method of claim 21 further comprising (d) reducing the compounds of formula 16 and removing the benzyl groups to yield at least one michellamine.
S»STtT TE9fEET WlE2β
PCT/US1995/014896 1994-11-15 1995-11-13 Method and intermediates for the synthesis of korupensamines WO1996015111A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42378/96A AU4237896A (en) 1994-11-15 1995-11-13 Method and intermediates for the synthesis of korupensamines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/339,958 1994-11-15
US08/339,958 US5543523A (en) 1994-11-15 1994-11-15 Method and intermediates for the synthesis of korupensamines

Publications (2)

Publication Number Publication Date
WO1996015111A1 WO1996015111A1 (en) 1996-05-23
WO1996015111A9 true WO1996015111A9 (en) 1996-08-01

Family

ID=23331301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014896 WO1996015111A1 (en) 1994-11-15 1995-11-13 Method and intermediates for the synthesis of korupensamines

Country Status (3)

Country Link
US (1) US5543523A (en)
AU (1) AU4237896A (en)
WO (1) WO1996015111A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579332B2 (en) 2004-07-27 2017-02-28 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140339A (en) 1994-02-14 2000-10-31 The United States Of America As Represented By The Department Of Health And Human Services Monomeric and dimeric arylisoquinoline alkaloids and derivatives thereof
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
NZ542342A (en) 2003-04-25 2009-05-31 Gilead Sciences Inc Antiviral phosphonate analogs
AU2004260789B2 (en) 2003-07-30 2011-06-30 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
DE602004021611D1 (en) 2003-09-19 2009-07-30 Gilead Sciences Inc AZACHINOLINOL PHOSPHONATE COMPOUNDS AS INTEGRASE INHIBITORS
EP2980095A1 (en) 2004-03-04 2016-02-03 K.U.Leuven Research & Development Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
BRPI0513426A (en) 2004-07-16 2007-11-27 Gilead Sciences Inc Amino Acid Preparation Process Useful in the Preparation of Peptide Receptor Modulators
CN101027303A (en) 2004-07-27 2007-08-29 吉里德科学公司 Imidazo 4,5-dpyrimidines, their uses and methods of preparation
TW201402124A (en) 2005-08-19 2014-01-16 Array Biopharma Inc 8-substituted benzoazepines as toll-like receptor modulators
GB0519169D0 (en) 2005-09-21 2005-10-26 Leuven K U Res & Dev Novel anti-viral strategy
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
CN101437816B (en) 2006-03-24 2013-08-14 阿雷生物药品公司 2-aminopyridine analogs as glucokinase activators
JP2009537546A (en) 2006-05-16 2009-10-29 ギリアード サイエンシーズ, インコーポレイテッド Integrase inhibitor
UA95641C2 (en) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
AR061840A1 (en) 2006-07-07 2008-09-24 Gilead Sciences Inc ANTIVIRAL PHOSPHINATE COMPOUNDS
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2008131501A2 (en) 2007-04-27 2008-11-06 Katholieke Universiteit Leuven New anti-viral nucleoside analogs
CA2692506C (en) 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US7893059B2 (en) 2007-09-24 2011-02-22 Genentech, Inc. Thiazolopyrimidine PI3K inhibitor compounds and methods of use
US8329709B2 (en) 2008-01-09 2012-12-11 Genentech, Inc. 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
CL2009001152A1 (en) 2008-05-13 2009-10-16 Array Biopharma Inc Compounds derived from n- (4- (nitrogen cycloalkyl-1-yl) -1h-pyrrolo [2,3-b] pyridin-3-yl) amide, kinase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a proliferative disease.
RU2561104C2 (en) 2008-06-20 2015-08-20 Дженентек, Инк. Triazolopyridine jak inhibitor compounds and methods
WO2010005986A1 (en) 2008-07-08 2010-01-14 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
AU2009308675A1 (en) 2008-10-31 2010-05-06 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
NZ619205A (en) 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
AR077033A1 (en) 2009-06-11 2011-07-27 Hoffmann La Roche INHIBITING COMPOUNDS OF JANUS KINASES AND THEIR USE IN THE TREATMENT OF IMMUNOLOGICAL DISEASES
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CN105669552A (en) 2009-08-18 2016-06-15 文蒂雷克斯药品公司 Substituted benzoazepines as TOLL-like receptor modulators
HUE032626T2 (en) 2009-08-18 2017-10-30 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators
WO2011025947A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2011025968A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase
CN102482283A (en) 2009-08-28 2012-05-30 阵列生物制药公司 Raf inhibitor compounds and methods of use thereof
SG178900A1 (en) 2009-08-28 2012-04-27 Genentech Inc Raf inhibitor compounds and methods of use thereof
JP2013503188A (en) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Raf inhibitory compounds and methods of use thereof
CN102858754A (en) 2009-08-28 2013-01-02 阵列生物制药公司 RAF inhibitor compounds and methods of use thereof
MX2012003591A (en) 2009-09-28 2012-04-19 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use.
ES2558742T3 (en) 2009-09-28 2016-02-08 F. Hoffmann-La Roche Ag Benzoxepine PI3K inhibitor compounds and methods of use
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
GB0921871D0 (en) 2009-12-15 2010-01-27 Univ Leuven Kath Novel antifungal compounds
ES2475970T3 (en) 2009-12-23 2014-07-11 Katholieke Universiteit Leuven Novel antiviral compounds
CN102712640A (en) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 Tricyclic heterocyclic compounds, compositions and methods of use thereof
US8440651B2 (en) 2010-02-22 2013-05-14 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP2547338A2 (en) 2010-03-17 2013-01-23 F. Hoffmann-La Roche AG Imidazopyridine compounds, compositions and methods of use
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
EP2556066B1 (en) 2010-04-07 2016-10-19 F.Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
CA2798634C (en) 2010-05-07 2019-04-16 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
CA2797872A1 (en) 2010-05-21 2011-11-24 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
RU2013104038A (en) 2010-07-14 2014-08-20 Ф. Хоффманн-Ля Рош Аг SELECTIVE WITH RESPECT TO PI3K p110 DELTA PURINE COMPOUNDS AND WAYS OF THEIR APPLICATION
BR112013006016A2 (en) 2010-09-15 2016-06-07 Hoffmann La Roche azabenzothiazole compounds, compositions and methods of use
EP2616074A1 (en) 2010-09-17 2013-07-24 Array Biopharma, Inc. Piperidinyl-substituted lactams as gpr119 modulators
KR20140003438A (en) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 Novel antiviral compounds
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Pharmasset Llc Antiviral compounds
WO2012066061A1 (en) 2010-11-19 2012-05-24 F. Hoffmann-La Roche Ag Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
TW201307357A (en) 2010-11-22 2013-02-16 Array Biopharma Inc Compounds for treating neurodegenerative diseases
CA3027814A1 (en) 2010-12-13 2012-06-21 Array Biopharma Inc. Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as intermediates for type iii receptor tyrosine kinase inhibitors
AR084312A1 (en) 2010-12-16 2013-05-08 Genentech Inc INHIBITING TRICICLIC COMPOUNDS OF THE PI3K AND PHARMACEUTICAL COMPOSITIONS
WO2012085003A1 (en) 2010-12-22 2012-06-28 Katholieke Universiteit Leuven, K.U. Leuven R&D 2-hydroxyisoquinoline-1,3(2h,4h)-diones and related compounds useful as hiv replication inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
HUE032036T2 (en) 2011-01-12 2017-08-28 Ventirx Pharmaceuticals Inc Substituted benzoazepines as toll-like receptor modulators
US20140088085A1 (en) 2011-01-12 2014-03-27 Array Biopharma, Inc Substituted Benzoazepines As Toll-Like Receptor Modulators
BR112013020329A2 (en) 2011-02-09 2016-08-02 Hoffmann La Roche heterocyclic compounds as pi3 kinase inhibitors
WO2012113920A1 (en) 2011-02-24 2012-08-30 Katholieke Universiteit Leuven Arylsulfone derivatives with activity against human betaherpesviruses
EP2681215B1 (en) 2011-02-28 2015-04-22 Array Biopharma, Inc. Serine/threonine kinase inhibitors
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
US9090628B2 (en) 2011-03-21 2015-07-28 Genentech, Inc. Benzoxazepin compounds selective for PI3K P110 delta and methods of use
CN103841976A (en) 2011-04-01 2014-06-04 基因泰克公司 Combinations of AKT AND MEK inhibitor compounds, and methods of use
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2739618B1 (en) 2011-08-04 2015-09-16 Array Biopharma, Inc. Quinazoline compounds as serine/threonine kinase inhibitors
EP2742046A1 (en) 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
CA2845409A1 (en) 2011-09-20 2013-03-28 Yingjie Lai Imidazopyridine compounds, compositions and methods of use
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
RU2638552C2 (en) 2011-09-27 2017-12-14 Ф. Хоффманн-Ля Рош Аг Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods for application
UA111756C2 (en) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
PE20141686A1 (en) 2011-11-03 2014-11-08 Hoffmann La Roche PIPERAZINE COMPOUNDS RENTED AS BTK ACTIVITY INHIBITORS
ES2552514T3 (en) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Bicyclic Piperazine Compounds
RU2622391C2 (en) 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Compound 8-fluorophthalazine-1(2h)-one as inhibitors of bruton tyrosine kinase
US20140309226A1 (en) 2011-11-16 2014-10-16 Array Biopharma Inc. Piperidinyl-substituted cyclic ureas as gpr119 modulators
PL2635588T3 (en) 2011-11-16 2015-10-30 Gilead Pharmasset Llc Condensed imidazolylimidazoles as antiviral compounds
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
UA116774C2 (en) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Serine/threonine kinase inhibitors
CA2865509A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfone and sulfoxide derivatives
WO2013127269A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido spirocyclic amide and sulfonamide derivatives
ES2620612T3 (en) 2012-03-02 2017-06-29 Genentech, Inc. Derivatives of pyridinyl and pyrimidinyl sulfoxides and sulfones
CN104395311B (en) 2012-04-23 2017-04-19 基因泰克公司 Intermediates and processes for preparing compounds
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
CA2871388A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag 5-azaindazole compounds and methods of use
JP6378182B2 (en) 2012-08-27 2018-08-22 アレイ バイオファーマ、インコーポレイテッド Hyperproliferative | Serine / threonine kinase inhibitor for treatment of disease
KR101697444B1 (en) 2012-08-30 2017-01-17 에프. 호프만-라 로슈 아게 Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
PL2900657T3 (en) 2012-09-26 2020-07-27 F.Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014089570A1 (en) 2012-12-07 2014-06-12 The General Hospital Corporation Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
KR101815360B1 (en) 2013-07-03 2018-01-04 에프. 호프만-라 로슈 아게 Heteroaryl pyridone and aza-pyridone amide compounds
JP6472803B2 (en) 2013-09-05 2019-02-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Triazolopyridine compounds, compositions thereof and methods of use
EP3052504B1 (en) 2013-10-04 2019-02-06 Universität Basel Conformationally restricted pi3k and mtor inhibitors
CA2929918C (en) 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
MX2016008624A (en) 2013-12-30 2017-01-06 Genentech Inc Serine/threonine kinase inhibitors.
MX2016012007A (en) 2014-03-18 2016-12-05 Hoffmann La Roche Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use.
RU2016149767A (en) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед ANALOGUES OF NICOTINAMIDRIBOSIDE AND PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION
JP6507234B2 (en) 2014-10-02 2019-04-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Pyrazole carboxamide compounds for use in the treatment of disorders mediated by bruton tyrosine kinase (BTK)
CN112457310A (en) 2014-12-18 2021-03-09 豪夫迈·罗氏有限公司 Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
ES2842749T3 (en) 2014-12-23 2021-07-14 Gilead Sciences Inc Processes for preparing ASK1 inhibitors
EP3262035A1 (en) 2015-02-25 2018-01-03 F. Hoffmann-La Roche AG Alkynyl alcohols and methods of use
WO2017001658A1 (en) 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN107873032B (en) 2015-07-02 2020-07-17 豪夫迈·罗氏有限公司 Benzoxazepine compounds and methods of use thereof
TW201720828A (en) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 Therapeutic compounds and compositions, and methods of use thereof
CN113999249A (en) 2015-12-16 2022-02-01 基因泰克公司 Methods for making tricyclic PI3K inhibitor compounds and methods of treating cancer therewith
CA3220447A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
WO2017216279A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
EP3472159A1 (en) 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN109641894B (en) 2016-08-24 2022-09-09 豪夫迈·罗氏有限公司 2-azabicyclo [3.1.0] hex-3-one derivatives and methods of use
WO2018037058A1 (en) 2016-08-24 2018-03-01 F. Hoffmann-La Roche Ag 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
BR112019004486A2 (en) 2016-09-06 2019-05-28 Hoffmann La Roche 8- (azetidin-1-yl) - [1,2,4] triazolo [1,5a] pyridinyl compounds, compositions and methods of use
CN110114343B (en) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 Pyrazolopyrimidine compounds and methods of use thereof
CA3137479A1 (en) 2017-03-03 2018-09-07 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
CN110494434B (en) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 Pyrazolophenyl compounds, compositions thereof, and methods of use thereof
CN110650959B (en) 2017-05-22 2023-04-18 豪夫迈·罗氏有限公司 Therapeutic compounds and compositions and methods of use thereof
JP7228318B6 (en) 2017-05-22 2023-03-10 エフ. ホフマン-ラ ロシュ アーゲー Therapeutic compounds and compositions, and methods of their use
SI3661937T1 (en) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
JP7339263B2 (en) 2018-01-15 2023-09-05 エフ. ホフマン-ラ ロシュ アーゲー Pyrazolopyrimidine compounds as JAK inhibitors
JP7320600B2 (en) 2018-09-12 2023-08-03 ジェネンテック, インコーポレイテッド Phenoxy-pyridyl-pyrimidine compounds and methods of use
US20220048888A1 (en) 2018-09-12 2022-02-17 Genentech, Inc. Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
KR102649419B1 (en) 2018-10-17 2024-03-21 어레이 바이오파마 인크. protein tyrosine phosphatase inhibitors
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI756636B (en) 2019-02-18 2022-03-01 美商建南德克公司 Pyrido-pyrimidinyl compounds and methods of use
CA3135555C (en) 2019-04-02 2023-09-19 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
JP2022536655A (en) 2019-06-11 2022-08-18 ジェネンテック, インコーポレイテッド Quinazolinyl compound and method of use
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
MA56518A (en) 2019-06-18 2022-04-27 Hoffmann La Roche JAK KINASES PYRAZOLOPYRIMIDINE SULPHONE INHIBITORS AND THEIR USES
JP2023526162A (en) 2020-03-30 2023-06-21 ユニベルシテ リブレ デ ブリュッセル Rel/RelA/SpoT small molecule modulators and screening methods
JP2023531742A (en) 2020-06-25 2023-07-25 ケムコム エス アー Use of compounds as self-tanning agents and tanning compositions thereof
KR20230113278A (en) 2020-09-30 2023-07-28 카톨리에케 유니버시테이트 루벤 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of YAP/TAZ-TEAD activation to treat cancer
US20230391739A1 (en) 2020-11-24 2023-12-07 Katholieke Universiteit Leuven Aryl derivatives for treating trpm3 mediated disorders
EP4251616A1 (en) 2020-11-24 2023-10-04 Katholieke Universiteit Leuven Heterocycle derivatives for treating trpm3 mediated disorders
CN116867792A (en) 2021-02-09 2023-10-10 基因泰克公司 Tetraepoxyazepine compound and use thereof
AU2022254674A1 (en) 2021-04-08 2023-10-12 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
CA3219784A1 (en) 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Methods of making a modulator of hemoglobin
TW202400170A (en) 2022-05-19 2024-01-01 美商建南德克公司 Aza-tetracyclic oxazepine compounds and uses thereof
WO2023227695A1 (en) 2022-05-25 2023-11-30 Katholieke Universiteit Leuven New derivatives for treating trpm3 mediated disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100066C (en) * 1991-04-12 1996-08-13 Michael R. Boyd Michellamines useful as antiviral agents, composition and method of treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579332B2 (en) 2004-07-27 2017-02-28 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds

Similar Documents

Publication Publication Date Title
WO1996015111A9 (en) Method and intermediates for the synthesis of korupensamines
US5543523A (en) Method and intermediates for the synthesis of korupensamines
AU599215B2 (en) A novel chemical intermediate of the synthesis of aromatic biocidal compounds
US5668285A (en) Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates
NO331656B1 (en) Process for synthesizing camptothesin related compounds
JP2001055377A (en) Intermediate for synthesizing raw material compound for camptothecin and its analogue
Kessar et al. Benzyne cyclization route to benzo [c] phenanthridine alkaloids. Synthesis of chelerythrine, decarine, and nitidine
US5166437A (en) Process for the preparation of fluoxetine
KR850000273B1 (en) Process for preparing 9-amino-1-hydroxy octahydro benzo(c)quinolines
IE46165B1 (en) Daunomycinone derivatives
Anderson et al. Synthesis and murine antineoplastic activity of bis [carbamoyloxymethyl] derivatives of pyrrolo [2, 1-a] isoquinoline
IE891076L (en) STEREOSPECIFIC PROCESS FOR THE PREPARATION OF FURO £3,4-c| PYRIDINE ENANTIOMERS AND COMPOUNDS THUS OBTAINED
JPH01139546A (en) 3,5-disubstituted-4-acetoxystyrene and its production
IE61297B1 (en) 3, 5-dihydroxy-6, 8-nonadienoic acids and derivatives as hypocholesterolemic agents
Szalai et al. Phototriggering of geometric dendrimer disassembly: an improved synthesis of 2, 4-bis (hydroxymethyl) phenol based dendrimers
PL164019B1 (en) Method of obtaining novel fluoronaphtacetodiones
US20050038024A1 (en) Novel artemisinine derivatives, and uses thereof for treating malaria
US5552550A (en) Monomeric Naphthylisoquinoline alkaloids and synthesis methods thereof
CN113698375A (en) Synthesis method of 4-cyclohexylimine methyl substituted benzofuran derivative
JP2832479B2 (en) Stereochemical inversion method of optically active styrene oxide and preparation of optically active glycol derivative
AU2002354049B2 (en) Photochromic oxazine compounds and methods for their manufacture
EP2368895A1 (en) Ferrocenyl flavonoids
Yang et al. A Stereoselective Route to (E)-Vinylic Selenides through the Palladium-Catalyzed Cross-Coupling Reaction of Selenovinylicdialkylboranes with Alkyl Halides
KATAYAMA et al. Amino-Claisen Rearrangement. IV. Quaternary Amino-Claisen Rearrangement of N-Allyljulolidinium Derivatives
JPH04169583A (en) Phenothiazine derivative and its production